Document is current
Any future updates will be listed below
-
Authors
Zhukovsky, Peter https://orcid.org/0000-0002-7181-2095
Kuhn, Manuel https://orcid.org/0000-0003-2210-9130
Borchers, Lauren R.
Ren, Boyu
Woronko, Sarah E. https://orcid.org/0000-0001-6517-4106
Li, Mohan https://orcid.org/0009-0008-6615-8077
Lam, Choi Sze Tracy
Zhang, Ethan M.
Ressler, Kerry J. https://orcid.org/0000-0002-5158-1103
Brennan, Brian P.
Vitaliano, Gordana https://orcid.org/0000-0002-9371-3733
Pizzagalli, Diego A. https://orcid.org/0000-0002-7772-1143
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH068376)
Wellcome Leap
- License Information
-
More Information
Article History
Received: 3 December 2025
Accepted: 13 May 2026
First Online: 6 July 2026
Competing interests
: Over the past 3 years, D.A.P. has received consulting fees from Abbvie, Boehringer Ingelheim, Circular Genomics, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, Neurocrine Biosciences, N1 Biocorp., Neuroscience Software, Syntropic Medical and Xenon Pharmaceuticals; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) and from Alkermes; he has received research funding from the Brain and Behavior Research Foundation, Circular Genomics, Dana Foundation, Wellcome Leap, Millennium Pharmaceuticals and NIMH; he has received stock options from Ceretype Neuromedicine, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics and Neuroscience Software. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. The other authors declare no competing interests.
